Teclistamab is a bispecific human monoclonal antibody to the B cell maturation antigen (BCMA) and CD3, which targets the antibody to T cells (T cell engager) and is used in the treatment of refractory or relapsing multiple myeloma.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.